Side Effects of Hydroxyurea in Patients with Sickle Cell Anemia

Background: hemoglobin s arises is the result of a point mutation (a-t) in the sixth codon on the -globin gene on chromosome 11 causing sickle cell anemia. the presence of fetal hemoglobin in infancy plays a relatively protective role for vaso-occlusive symptoms that are the major contributor for the morbidity and mortality among patients with sickle cell anemia. hydroxyurea, an s-phase-specific and non-dna-hypomethylating chemotherapeutic agent is capable of inducing hbf synthesis. materials and methods: we reviewed the records of 28 sickle cell anemia patients, aged 4-52 years, treated with hydroxyurea to study the drug’s side effects. results: in our study, the most common adverse effect was dermatologic complication which occurred in 15 patients (53.5%). the gastrointestinal side effects were nausea, vomiting, abdominal pain and anorexia occurring in 3 patients 10.7%. the neurologic adverse effects were uncommon and occurred in 4 patients (14.3%). conclusion: side effects of hydroxyurea were common but mild to moderate, benign and transient. starting a low dose of hydroxyurea (10 mg/kg per day) and increasing the dose slowly in pediatric and adult patients with sickle cell anemia can be tolerated well, without serious side effects.